BidaskClub Lowers Merit Medical Systems (MMSI) to Sell

Merit Medical Systems (NASDAQ:MMSI) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a report issued on Friday, BidAskClub reports.

Other equities analysts have also recently issued research reports about the stock. ValuEngine cut shares of Merit Medical Systems from a “buy” rating to a “hold” rating in a research report on Thursday, April 25th. Needham & Company LLC reiterated a “buy” rating on shares of Merit Medical Systems in a research report on Thursday, April 25th. Finally, Zacks Investment Research upgraded shares of Merit Medical Systems from a “hold” rating to a “buy” rating and set a $62.00 price target on the stock in a research report on Tuesday, April 30th. Two analysts have rated the stock with a sell rating, one has given a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $67.80.

Shares of NASDAQ MMSI opened at $52.75 on Friday. Merit Medical Systems has a 1 year low of $47.30 and a 1 year high of $66.34. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.25 and a current ratio of 2.36. The stock has a market cap of $2.90 billion, a P/E ratio of 31.21, a P/E/G ratio of 2.29 and a beta of 1.03.



Merit Medical Systems (NASDAQ:MMSI) last announced its quarterly earnings results on Tuesday, April 23rd. The medical instruments supplier reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.36 by $0.01. Merit Medical Systems had a net margin of 4.68% and a return on equity of 10.99%. The company had revenue of $238.35 million for the quarter, compared to analysts’ expectations of $236.53 million. During the same quarter in the previous year, the company earned $0.31 earnings per share. Merit Medical Systems’s quarterly revenue was up 17.4% on a year-over-year basis. As a group, equities analysts predict that Merit Medical Systems will post 2.02 EPS for the current fiscal year.

In other Merit Medical Systems news, Director Michael E. Stillabower sold 10,000 shares of the company’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $58.05, for a total value of $580,500.00. Following the sale, the director now owns 63,618 shares in the company, valued at $3,693,024.90. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Kent W. Stanger sold 1,216 shares of the company’s stock in a transaction dated Tuesday, March 26th. The stock was sold at an average price of $60.54, for a total transaction of $73,616.64. The disclosure for this sale can be found here. In the last 90 days, insiders sold 43,216 shares of company stock worth $2,579,837. Corporate insiders own 4.75% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. Bessemer Group Inc. purchased a new stake in Merit Medical Systems in the fourth quarter worth about $2,350,000. Roubaix Capital LLC bought a new position in shares of Merit Medical Systems in the first quarter worth approximately $4,352,000. Amundi Pioneer Asset Management Inc. bought a new position in shares of Merit Medical Systems in the fourth quarter worth approximately $4,147,000. MML Investors Services LLC bought a new position in shares of Merit Medical Systems in the fourth quarter worth approximately $504,000. Finally, Bank of America Corp DE lifted its stake in shares of Merit Medical Systems by 6.5% in the fourth quarter. Bank of America Corp DE now owns 379,199 shares of the medical instruments supplier’s stock worth $21,164,000 after buying an additional 23,277 shares in the last quarter. Institutional investors and hedge funds own 97.45% of the company’s stock.

Merit Medical Systems Company Profile

Merit Medical Systems, Inc manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates through Cardiovascular and Endoscopy segments. It provides peripheral intervention products, including access, angiography, intervention, and drainage and biopsy for diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, and electrophysiology and cardiac rhythm management products to treat various heart conditions.

Further Reading: How to Use a Moving Average for Trading 

Analyst Recommendations for Merit Medical Systems (NASDAQ:MMSI)

Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.